Signs MoU with Apollo Hospitals- Zydus Lifesciences Ltd

Code BSE: 532321 NSE: $ZYDUSLIFE Zydus signs MoU with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection test (MCD) in India Speaking on this development, Dr. Prathap C. Reddy, Chairman, Apollo Hospitals Group, said, "At Apollo, we have long believed that the most effective healthcare is proactive healthcare. The future of medicine lies not only in treating disease, but in preventing it and detecting it at its earliest, most treatable stages. Cancer continues to be one of the greatest health challenges facing societies worldwide, and expanding access to timely, reliable screening, is critical to reducing its impact. Our collaboration with Zydus Lifesciences marks an important milestone in advancing accessible, patient-friendly cancer screening solutions for the people of India. By bringing together innovation, scientific excellence, and a shared commitment to better health outcomes, we can empower individuals to take charge of their health, enable earlier diagnosis, and significantly improve the chances of successful treatment. Together, we are taking another meaningful step toward a future where more lives are saved through early detection and timely intervention."